HAYA Therapeutics Announces Collaboration with Eli Lilly
HAYA Therapeutics SA, a Swiss biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics, announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions.
Sale of T3 Pharmaceuticals AG to Boehringer Ingelheim
T3 Pharmaceuticals AG, a biotechnology company with its headquarter in Allschwil, Switzerland has been acquired by Boehringer Ingelheim, a leading family-owned, research-driven biopharmaceutical company based in Ingelheim, Germany...
LASCCO and Abionic enter license agreement with Fapon
LASCCO SA, a biomedical-technology company, and Abionic SA, a nanotechnology company, both based at the Biopôle of Lausanne, Switzerland, entered into a licensing agreement with Fapon Biotech, a global leading life sciences company, based in Dongguan, China, for the use of the pancreatic stone protein (PSP) biomarker for sepsis diagnosis in China.
Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients
Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF25 million series C financing round led by Pureos Bioventures.
VISCHER advised the sellers and the management on the sale of the Mimacom Flowable Group to Ardian
The shareholders of the Mimacom Flowable Group ("MFG") have sold MFG to the private equity investment house Ardian, accompanied by a reinvestment of the management. The transaction was completed on 19 April 2023. Headquartered in...
Medartis increases stake in KeriMedical
Medartis (SIX: MED), a Basel-based orthopedic company specializing in head and extremity surgery, recently signed an agreement with the private founders of KeriMedical, a Geneva-based private company specializing in the development and manufacture of implants for hand and wrist surgery, to acquire an additional 18% stake for a purchase price of approximately CHF 18m.
SHS invests in Simulands AG
The German life science and medtech investor SHS Gesellschaft für Beteiligungsmanagement mbH has made a EUR 10 million investment in Simulands AG, a Zurich-based manufacturer of simulation devices for medical training of cardiovascular interventions.
Novaremed and NeuroFront enter option and license agreement for NRD.E1
Novaremed AG, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics (Hong Kong) Limited, a China-based clinical stage neuroscience biotech company, jointly announced the signing of an exclusive collaboration and commercialization agreement for Novaremed’s innovative non-opioid investigational drug, NRD.E1, being developed for the treatment of diabetes-related neuropathic pain and other neuropathic pain indications.
Eurocine and Redbiotec partner to develop HSV-2 vaccines
Eurocine Vaccines and Redbiotec have signed a research and partnership agreement for the development of vaccine candidates against Herpes Simplex Virus Type 2 (HSV-2).
CombiGene and Spark enter global licensing agreement for gene therapy
STOCKHOLM - CombiGene AB and Spark Therapeutics announced the signing of an exclusive collaboration and licensing agreement for CombiGene’s CG01 project.